Metastatic or locally advanced breast cancer patients: towards an expert consensus on nab-paclitaxel treatment in HER2-negative tumours—the MACBETH project
Valter Torri(Istituti di Ricovero e Cura a Carattere Scientifico), José Á. García-Sáenz(Hospital Clínico San Carlos), Christian Schem(Krankenhaus Jerusalem), Marina Elena Cazzaniga(Azienda Ospedaliera San Gerardo), Alessandra Fabi(Agostino Gemelli University Polyclinic), Eleni Timotheadou(Aristotle University of Thessaloniki), Khalil Zaman, Henrik Lindman(Uppsala University), Eva Ciruelos(Hospital Universitario 12 De Octubre), G. Steger(Aristotle University of Thessaloniki), D. Mavroudis(University Hospital of Heraklion)
Cited by 5
Related Papers
De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017
|Annals of Oncology|2017|1.3k
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study
|The Lancet Oncology|2015|1.1k
Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial
|The Lancet Oncology|2016|1k
Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast Cancer
|New England Journal of Medicine|2014|751
Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer
|New England Journal of Medicine|2018|684